Cargando…

The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting

BACKGROUND: Little is known about the pathway to diagnosis of lymphoma in Sub-Saharan Africa, despite the increased risk of lymphoma in people living with HIV (PLHIV). The challenges of diagnosis in this setting include diagnostic confusion with extrapulmonary tuberculosis (EPTB), which commonly cau...

Descripción completa

Detalles Bibliográficos
Autores principales: Antel, Katherine, Levetan, Carly, Mohamed, Zainab, Louw, Vernon J, Oosthuizen, Jenna, Maartens, Gary, Verburgh, Estelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485177/
https://www.ncbi.nlm.nih.gov/pubmed/31023278
http://dx.doi.org/10.1186/s12885-019-5586-4
_version_ 1783414232658739200
author Antel, Katherine
Levetan, Carly
Mohamed, Zainab
Louw, Vernon J
Oosthuizen, Jenna
Maartens, Gary
Verburgh, Estelle
author_facet Antel, Katherine
Levetan, Carly
Mohamed, Zainab
Louw, Vernon J
Oosthuizen, Jenna
Maartens, Gary
Verburgh, Estelle
author_sort Antel, Katherine
collection PubMed
description BACKGROUND: Little is known about the pathway to diagnosis of lymphoma in Sub-Saharan Africa, despite the increased risk of lymphoma in people living with HIV (PLHIV). The challenges of diagnosis in this setting include diagnostic confusion with extrapulmonary tuberculosis (EPTB), which commonly causes lymphadenopathy in PLHIV. METHODS: We analysed the time to diagnosis and treatment in patients using predetermined time intervals. Univariate and multivariable analyses were performed to determine the relationship between patient and disease-specific variables with delays to diagnosis. We were particularly interested in the impact of HIV, empiric tuberculosis therapy and fine-needle aspirate for cytology (FNAC) in contributing to delay. RESULTS: Patients (n = 163), 29% HIV-infected, waited a median of 4 weeks before seeking medical attention. It took a median of 7 weeks for the diagnosis of lymphoma to be made from the time the patient sought medical attention, termed the healthcare practitioner interval. In multivariable logistic regression analysis, diagnostic delay > 6 weeks was associated with late-stage disease (OR 2.3, 95% CI 1.1–5.2) and Hodgkin lymphoma (HL) (OR 3.0, 95% CI 1.1–8.0). HIV status was not associated with diagnostic delay (OR 0.9, 95% CI 0.3–2.2). The median time to diagnosis was a median of 4 weeks longer for patients on tuberculous (TB) therapy (n = 16, p = 0.28) and patients who underwent an FNAC (n = 63, p = 0.04). Where FNAC was performed, it was diagnostic for lymphoma in only 11%. Diagnostic delay was not associated with overall survival. CONCLUSIONS: Time-to-diagnosis of lymphoma in South Africa was similar to that reported from high-income countries and shows significant periods of delay between the onset of symptoms to diagnosis and treatment. The longest period of delay was in the health practitioner interval. Education regarding the significance of lymphadenopathy for both patients and health care practitioners and appropriate investigative steps preferably by best-practice algorithms specific to TB-endemic areas are needed to shorten the time-to-diagnosis of lymphoma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5586-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6485177
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64851772019-05-03 The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting Antel, Katherine Levetan, Carly Mohamed, Zainab Louw, Vernon J Oosthuizen, Jenna Maartens, Gary Verburgh, Estelle BMC Cancer Research Article BACKGROUND: Little is known about the pathway to diagnosis of lymphoma in Sub-Saharan Africa, despite the increased risk of lymphoma in people living with HIV (PLHIV). The challenges of diagnosis in this setting include diagnostic confusion with extrapulmonary tuberculosis (EPTB), which commonly causes lymphadenopathy in PLHIV. METHODS: We analysed the time to diagnosis and treatment in patients using predetermined time intervals. Univariate and multivariable analyses were performed to determine the relationship between patient and disease-specific variables with delays to diagnosis. We were particularly interested in the impact of HIV, empiric tuberculosis therapy and fine-needle aspirate for cytology (FNAC) in contributing to delay. RESULTS: Patients (n = 163), 29% HIV-infected, waited a median of 4 weeks before seeking medical attention. It took a median of 7 weeks for the diagnosis of lymphoma to be made from the time the patient sought medical attention, termed the healthcare practitioner interval. In multivariable logistic regression analysis, diagnostic delay > 6 weeks was associated with late-stage disease (OR 2.3, 95% CI 1.1–5.2) and Hodgkin lymphoma (HL) (OR 3.0, 95% CI 1.1–8.0). HIV status was not associated with diagnostic delay (OR 0.9, 95% CI 0.3–2.2). The median time to diagnosis was a median of 4 weeks longer for patients on tuberculous (TB) therapy (n = 16, p = 0.28) and patients who underwent an FNAC (n = 63, p = 0.04). Where FNAC was performed, it was diagnostic for lymphoma in only 11%. Diagnostic delay was not associated with overall survival. CONCLUSIONS: Time-to-diagnosis of lymphoma in South Africa was similar to that reported from high-income countries and shows significant periods of delay between the onset of symptoms to diagnosis and treatment. The longest period of delay was in the health practitioner interval. Education regarding the significance of lymphadenopathy for both patients and health care practitioners and appropriate investigative steps preferably by best-practice algorithms specific to TB-endemic areas are needed to shorten the time-to-diagnosis of lymphoma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5586-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-25 /pmc/articles/PMC6485177/ /pubmed/31023278 http://dx.doi.org/10.1186/s12885-019-5586-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Antel, Katherine
Levetan, Carly
Mohamed, Zainab
Louw, Vernon J
Oosthuizen, Jenna
Maartens, Gary
Verburgh, Estelle
The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting
title The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting
title_full The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting
title_fullStr The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting
title_full_unstemmed The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting
title_short The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting
title_sort determinants and impact of diagnostic delay in lymphoma in a tb and hiv endemic setting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485177/
https://www.ncbi.nlm.nih.gov/pubmed/31023278
http://dx.doi.org/10.1186/s12885-019-5586-4
work_keys_str_mv AT antelkatherine thedeterminantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT levetancarly thedeterminantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT mohamedzainab thedeterminantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT louwvernonj thedeterminantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT oosthuizenjenna thedeterminantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT maartensgary thedeterminantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT verburghestelle thedeterminantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT antelkatherine determinantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT levetancarly determinantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT mohamedzainab determinantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT louwvernonj determinantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT oosthuizenjenna determinantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT maartensgary determinantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting
AT verburghestelle determinantsandimpactofdiagnosticdelayinlymphomainatbandhivendemicsetting